NEW YORK (GenomeWeb News) – Luminex and High Throughput Genomics have partnered to develop an integrated assay that Luminex will sell to the gene expression research market.
Luminex said today that the new qBead Gene Expression Assay puts HTG's qNPA chemistry technology on the Luminex xMAP multiplexing platform to create a high-throughput assay with a simplified workflow that requires no extractions, cDNA synthesis, or amplifications, Luminex said today.
The qBead assay is used to acquire gene expression data from degraded samples or difficult samples, such as formalin-fixed paraffin-embedded and other fixed tissues.
"The combination of xMAP Technology from Luminex and the qBead Assay represents an advance for many scientists, including cancer researchers who perform retrospective studies on large numbers of archived samples," Luminex CEO and President Patrick Balthrop said in a statement.
Balthrop also said that the partnership will use the two firms' technologies "to create high-throughput, custom assays that will advance the work of researchers in the critical, growing mid-plex custom gene expression research arena."